본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Kidney international, Supplement no.53, 1996년, pp.44 - 50  

A dose-searching trial of an anti-LFA1 monoclonal antibody in first kidney transplant recipients.

Le Mauff, B Le Meur, Y Hourmant, M Debray, M Boeffard, F Alberici, G Soulillou, J P Scherrmann, J M
  • 초록  

    25.3, a mouse IgG1 monoclonal antibody (MoAb), directed at the alpha chain of the LFA1 molecule (CD11a) has been used in prophylaxis of rejection in recipients of cadaveric kidney graft. Promising clinical results have been obtained for both tolerance and efficacy [1]. The aim of this trial was to determine the optimal dosage, base on a pharmacokinetic-pharmacodynamic analysis of the data obtained from the 15 patients included in this dose-searching study. Biological parameters, such as circulating levels and functional inhibition (as detected in an adhesion assay of patient lymphocytes), were measured during and after treatment. A Hill relation was calculated between the effect and the concentration measured and led us to select a 15 mg/day dose for further clinical trials, with a loading dose of 30 mg. An additional group receiving this protocol was submitted to the same calculation, and the results from this last group were in agreement with this previous analysis.


  • 원문보기

    원문보기
    무료다운로드 유료다운로드
    • 무료 원문 정보가 존재하지 않습니다.
    • 유료 원문 정보가 존재하지 않습니다.

    유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역